文献速递心外重症与机械循环支持

超越阿喀琉斯之踵:驱动线感染是持久性左心室辅助装置治疗的「癌症」

Beyond the Achilles Heel: Driveline infection as the cancer of durable LVAD therapy.
PubMed 文献 · J Heart Lung Transplant · 2026-08-22

持久性左心室辅助装置(LVAD)显著改善晚期心衰患者生存,但驱动线感染(DLI)在5年内影响40%患者。作者提出应将DLI视为LVAD治疗的「癌症」,因其呈慢性、复发性、治疗抵抗和进展性病程,并据此建议按解剖范围和侵袭性指导治疗、系列分期和多学科评估。

要点

  • DLI在5年内影响40%的LVAD患者,呈慢性、复发性、进展性病程。
  • DLI管理应参照癌症原则:按解剖范围和侵袭性分层,抑制不等于治愈。
  • 深部DLI可考虑LVAD移除、心脏移植或装置更换,但需在感染广泛扩散前干预。

核心结论

  • 提议将驱动线感染视为LVAD治疗的「癌症」,该类比为临床类比而非生物学类比,可指导治疗策略。

研究设计与样本

  • 本文为观点/综述类文章,未报告系统检索范围或样本量。

主要发现

  • DLI在5年内影响40%的LVAD患者。
  • DLI从出口部位开始,经生物膜形成持续存在,表面缓解后复发,沿驱动线进展,最终可能累及泵和流出道血管。
  • DLI反复导致患者因静脉抗生素和手术住院,并最终导致死亡。

关键数值与推荐

  • DLI的治疗应参照癌症,按解剖范围和疾病侵袭性指导管理。
  • 抑制治疗不应被误认为治愈。
  • 根治性干预应在晚期扩散前进行,因为此时感染源控制变得更困难。
  • 建议进行系列分期和多学科评估,当感染在抑制治疗下仍进展时考虑移除硬件。
  • 深部DLI的潜在根治选项包括:心肌恢复充分者移除LVAD、符合条件者心脏移植、不适合移植者更换装置。

临床怎么用

  • 每个LVAD项目必须优先实施从植入到整个支持期的规范化预防。
  • 对DLI患者进行系列分期和多学科评估,按解剖范围和侵袭性决策。
  • 深部DLI在抑制治疗下进展时考虑硬件移除,根治性干预应尽早。

局限性

  • 「癌症」类比为临床类比而非生物学类比。
  • 原文未报告系统检索范围或研究样本量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Durable left ventricular assist devices (LVADs) have transformed survival in advanced heart failure, yet driveline infection (DLI) affects 40% of patients by 5 years. The term "Achilles' heel" identifies the driveline as the system's critical vulnerability but does not capture the course of DLI. Achilles died acutely from a heel wound; DLI is chronic, recurrent, treatment-resistant, and progressive. It begins at the exit site, persists through biofilm formation, recurs after apparent remission, progresses along the driveline, and may eventually involve the pump and outflow graft, repeatedly exposing patients to hospitalizations for intravenous antibiotics and surgery, and ultimately causing death. We therefore propose that DLI be viewed as the "cancer" of LVAD therapy. The analogy is clinical, not biological, and informs treatment: as with cancer, management should be guided by anatomic extent and disease aggressiveness, suppression should not be mistaken for cure, and definitive intervention should precede advanced spread, when source control becomes more difficult. Serial staging and multidisciplinary review are recommended, with hardware removal considered when infection progresses despite suppressive therapy. Potentially curative options for deep DLI include LVAD explantation in patients with sufficient myocardial recovery, transplantation for eligible candidates, and device exchange when transplantation is not feasible. Given the major challenges of treating DLI, every LVAD program must prioritize protocolized prevention from implantation throughout support. Ultimately, eliminating the cancer of LVAD therapy will require a fully implantable system with no driveline to infect.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Colombo PC, Yuzefpolskaya M. Beyond the Achilles Heel: Driveline infection as the cancer of durable LVAD therapy. J Heart Lung Transplant. 2026. PMID: 42632623. doi:10.1016/j.healun.2026.08.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。